KR930703262A - Imidazolidinone Compound - Google Patents

Imidazolidinone Compound

Info

Publication number
KR930703262A
KR930703262A KR1019930701375A KR930701375A KR930703262A KR 930703262 A KR930703262 A KR 930703262A KR 1019930701375 A KR1019930701375 A KR 1019930701375A KR 930701375 A KR930701375 A KR 930701375A KR 930703262 A KR930703262 A KR 930703262A
Authority
KR
South Korea
Prior art keywords
cyclopentyloxy
methoxyphenyl
imidazolidinone
compound
alkyl
Prior art date
Application number
KR1019930701375A
Other languages
Korean (ko)
Inventor
엘리오트 벤더 폴
4세 시그프리드 벤자민 크리스텐센
Original Assignee
스튜어트 알. 슈터
스미스클라인 비참 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스튜어트 알. 슈터, 스미스클라인 비참 코포레이션 filed Critical 스튜어트 알. 슈터
Publication of KR930703262A publication Critical patent/KR930703262A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/32—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C271/34—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of rings other than six-membered aromatic rings with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Abstract

종양괴사인자의 생성을 억제시키고 TNF생성에 의해 중재되었거나 악화된 질병상태를 치료하는데 유용한 신규의 이미다졸리디논 유도체가 기술된다. 본 발명의 화합물은, 또한, PDE IV의 억제인자로서 유용하며, 따라서, PDE IV의 중재 또는 억제가 필요한 질병상태를 치료하는데 유용하다.Novel imidazolidinone derivatives are described that are useful for inhibiting the production of tumor necrosis factor and for treating a disease state mediated or exacerbated by TNF production. The compounds of the present invention are also useful as inhibitors of PDE IV and, therefore, useful for treating disease states that require the intervention or inhibition of PDE IV.

Description

이미다졸리디논 화합물Imidazolidinone Compound

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (36)

하기 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염:A compound of formula (I) or a pharmaceutically acceptable salt thereof: 상기식에서, R1은 -(CR9R10)n-(C(O)O)r-(CR9R10)m-R8, -(CR9R10)n-(C(O)NR6)r-(CR9R10)m-R8, 또는 -(CR9R10)n-(C)s-(CR9R10)m-R8이고, 여기서, 알킬잔기는 하나이상의 할로겐에 의해 임의로 치환될 수 있고, n은 0내지 4의 수이고, m은 0내지 2의 수이고, r은 0또는 1의 수이고, s는 0또는 1의 수이고, R9및 R10은 수소 또는 C1-2알킬중에서 독립적으로 선택되고, R8은 수소, 메틸, 하이드록실, 테트라하이드로푸란, 테트라하이드로피란, 테트라하이드로티오펜, 테트라하이드로티오피란, C3-6사이클로알킬, 또는 한개 또는 두개의 불포화결합을 함유한 C4-6사이클로알킬이고, 여기서, 사이클로알킬 및 헤테로사이클잔기는 1내지 3개의 메틸그룹 또는 한개의 에틸그룹에 의해 임의로 치환될 수 있고, 단, a) r이 1일때, n은 1내지 4이거나, b) s가 1일때, n은 2내지 4이거나, c) R8이 하이드록실이고, r이 1이고, n이 1내지 4일때, m은 2이거나, d) R8이 하이드록실이고, r또는 s가 0일때, n+m의 합이 2내지 6이거나, e) -(CR9R10)n-(C(O)O)r-(CR9R10)m-R8에서 m이 0이고, r이 1일때, n은 1내지 4이거나, f) R5이 2-테트라하이드로피란 또는 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, r또는 s가 0일때, n+m의 합이 1내지 6이거나, g)R8이 2-테트라하이드로피란, 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, n이 1내지 4이고, r이 1일때, m은 1내지 2이어야하거나, h) R8이 2-테트라하이드로피란, 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, n은 2내지 4이고, s는 1일때, m은 1내지 2이어야하고, X는 YR2, 할로겐, 니트로, NR6R7또는 포르밀아민이고, 여기서, Y는 0또는 S(O)m′이고, m′은 0내지 2의 수이고, R6및 R7은 하기정의한 바와같고, R2는 1개이상의 할로겐에 의해 임의로 치환된 -CH3또는 -CH2CH3이고, R3은 H, CH3, CN, CH2F, CHF2, 또는 CF3이고, R4는 H, C1-C4알킬, OH, OCH3, OCH2CH3, 또는 OAc이고, R5는 H, OH, (CH2)qAr, 또는 C1-6알킬이고, 여기서, -(CH2)qAr, 또는 C1-6알킬그룹은 F, Br, Cl, -NO2, -NR6R7, -CO2R6, -OR6, -OC(O)R6, C(O)R6, CN, -C(O)-NR6R7, -C(S)-NR6R7, -NR6-C(O)-NR6R7, -NR6-C(S)-NR6R7, -NR6-C(O)-R6, -NR6-C(S)-R6, -NR6-C(O)-OR6, C(=-NR6)--NR6R4, -C(=NCN)-NR6R7, -C(=NCN)-SR6, -NR6-C(=NCN)-SR6, -NR6-C(=NCN)-NR6R7, -C(=NR6R7)SR6, -NR6-S(O)2-R6, -S(O)m'-R6, -NR6SO2-CF3, -NR6C(O)-C(O)-NR6R7, -NR6-C(O)-C(O)-OR6, 1-이미다졸릴 또는 1-(NR6)-2-이미다졸릴에 의해 한번이상 임으로 치환되고, Ar은 2-,3- 또는 4-피리딜, 피리미딜, 피라질, 이미다졸릴, 모르폴리노, 4- 또는 5-티아졸릴, 트리아졸릴, 2-또는 3-티에닐, 2-티아펜 또는 페닐이고, R6및 R7은 독립적으로 수소이거나, 한개 이상의 할로겐에 의해 임의로 치환된 C1-4알킬이고, q는 0내지 2의 수이다.Wherein R 1 is-(CR 9 R 10 ) n- (C (O) O) r- (CR 9 R 10 ) m -R 8 ,-(CR 9 R 10 ) n- (C (O) NR 6 ) r- (CR 9 R 10 ) m -R 8 , or-(CR 9 R 10 ) n- (C) s- (CR 9 R 10 ) m -R 8 , wherein the alkyl residue is one or more halogen May be optionally substituted by n is 0 to 4, m is 0 to 2, r is 0 or 1, s is 0 or 1, and R 9 and R 10 are Independently selected from hydrogen or C 1-2 alkyl, R 8 is hydrogen, methyl, hydroxyl, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, C 3-6 cycloalkyl, or one Or C 4-6 cycloalkyl containing two unsaturated bonds, wherein the cycloalkyl and heterocycle residues may be optionally substituted by one to three methyl groups or one ethyl group, provided that a) r is When 1, n is 1 to 4, or b) when s is 1, n is 2 Not 4 or, c) R and 8 is hydroxyl, and r is 1, or n is 1 to 4 when, m is 2, d) R and 8 is hydroxyl, r, or s of a is 0, n + m When the sum is 2 to 6 or e)-(CR 9 R 10 ) n- (C (O) O) r- (CR 9 R 10 ) m -R 8 , when m is 0 and r is 1, n is 1 to 4 or f) when R 5 is 2-tetrahydropyran or 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene and r or s is 0, the sum of n + m is 1 to 6, or g) when R 8 is 2-tetrahydropyran, 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene, n is 1-4 and r is 1, m Is 1 to 2, or h) when R 8 is 2-tetrahydropyran, 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene, n is 2 to 4 and s is 1 , m is 1 or 2, and must be, X is YR 2, halogen, you A, NR 6 R 7 or formyl amine, wherein, "a, m, Y is O or S (O) m is a number of 0 to 2, R 6 and R 7 are as defined for, R 2 is -CH 3 or -CH 2 CH 3 , optionally substituted by one or more halogens, R 3 is H, CH 3 , CN, CH 2 F, CHF 2 , or CF 3 , and R 4 is H, C 1- C 4 alkyl, OH, OCH 3 , OCH 2 CH 3 , or OAc, R 5 is H, OH, (CH 2 ) q Ar, or C 1-6 alkyl, wherein — (CH 2 ) q Ar, Or C 1-6 alkyl group is F, Br, Cl, -NO 2 , -NR 6 R 7 , -CO 2 R 6 , -OR 6 , -OC (O) R 6 , C (O) R 6 , CN , -C (O) -NR 6 R 7 , -C (S) -NR 6 R 7 , -NR 6 -C (O) -NR 6 R 7 , -NR 6 -C (S) -NR 6 R 7 , -NR 6 -C (O) -R 6, -NR 6 -C (S) -R 6, -NR 6 -C (O) -OR 6, C (= - NR 6) - NR 6 R 4 , -C (= NCN) -NR 6 R 7 , -C (= NCN) -SR 6 , -NR 6 -C (= NCN) -SR 6 , -NR 6 -C (= NCN) -NR 6 R 7 , -C (= NR 6 R 7 ) SR 6 , -NR 6 -S (O) 2 -R 6 , -S (O) m ' -R 6 , -NR 6 SO 2 -CF 3 , -NR 6 C (O) -C (O) -NR 6 R 7, -NR 6 -C (O) -C (O) -OR 6, 1- imidazolyl or 1- (NR 6) -2- imidazolyl Is substituted one or more times, and Ar is 2-, 3- or 4-pyridyl, pyrimidyl, pyrazyl, imidazolyl, morpholino, 4- or 5-thiazolyl, triazolyl, 2-or 3- Thienyl, 2-thiaphene or phenyl, R 6 and R 7 are independently hydrogen or C 1-4 alkyl optionally substituted by one or more halogens, q is a number from 0 to 2. 제1항에 있어서, 할로겐이 불소인 화합물.The compound of claim 1 wherein the halogen is fluorine. 제1항 또는 2항에 있어서, X가 YR2인 화합물.The compound of claim 1 or 2, wherein X is YR 2 . 3항에 있어서, Y가 산소인 화합물.The compound of claim 3, wherein Y is oxygen. 제1항, 2항 또는 3항에 있어서, R5가 H, 임의로 치환된 -(CH2)qAr 또는 임의로 치환된 C1-6알킬인 화합물.4. A compound according to claim 1, 2 or 3 wherein R 5 is H, optionally substituted-(CH 2 ) q Ar or optionally substituted C 1-6 alkyl. 제1항 내지 5항중 한 항에 있어서, R1이 사이클로펜틸.6. The cyclopentyl of claim 1, wherein R 1 is cyclopentyl. CH2CF3, CH2CHF2또는 CH3인 화합물.CH 2 CF 3 , CH 2 CHF 2 or CH 3 . 제6항에 있어서 R2가 메틸, -CF3, CF2H 또는 -CH2CHF2인 화합물.The compound of claim 6, wherein R 2 is methyl, —CF 3 , CF 2 H or —CH 2 CHF 2 . 제7항에 있어서, R4가 수소, 메틸 또는 메톡시이고, R3이 CN, CHF2, CF3또는 H의 화합물.8. A compound of claim 7, wherein R 4 is hydrogen, methyl or methoxy and R 3 is CN, CHF 2 , CF 3 or H. 제5항에 있어서, R5가 H 또는 임의의 치환된 -(CH2)qAr인 화합물.6. The compound of claim 5, wherein R 5 is H or optionally substituted — (CH 2 ) q Ar. 제8항 또는 제9항에 있어서, Ar이 페닐 또는 치환된 페닐이고 q가 1인 화합물.10. The compound of claim 8 or 9, wherein Ar is phenyl or substituted phenyl and q is 1. 제10항에 있어서, 임의 치환체가 Br, Cl, NO2, NR6R7, CO2R6, -NH-C(=NCN)-SCH3,-NHC(O)-NR6R7, -C(O)NR6R7, -NHC(O)CH3, -NH-(=NCN)-NR6R7, -NHC(O)C(O)-NR6R7, -NHSO2CH3, -S(O)mCH3, -NHC(O)C(O)-OR6,-OR6, -CN, -C(=NR6)-NR6R7, -NHSO2CF3,The compound of claim 10, wherein the optional substituents are Br, Cl, NO 2 , NR 6 R 7 , CO 2 R 6 , -NH-C (= NCN) -SCH 3, -NHC (O) -NR 6 R 7 ,- C (O) NR 6 R 7 , -NHC (O) CH 3 , -NH-(= NCN) -NR 6 R 7 , -NHC (O) C (O) -NR 6 R 7 , -NHSO 2 CH 3 , -S (O) m CH 3 , -NHC (O) C (O) -OR 6 , -OR 6 , -CN, -C (= NR 6 ) -NR 6 R 7 , -NHSO 2 CF 3 , 중에서 선택되는 화합물. Compound selected from among. 제11항에 있어서, 임의 치환제가 -NH2, -N(CH3)2, -S(O)mCH3, -NH-C(O)-CH3, -CO2CH3, OCH3, CO2H, NO2, -NH-C(=NCN)-SCH3, -NH-C(=NCN)-NH2, -NH-C(O)-NH2, -NH-C(O)-C(O)-OR6, 또는 -NH-C(O)-C(O)-NR6R7중에서 선택되는 화합물.The method of claim 11, wherein the optional substituent is -NH 2 , -N (CH 3 ) 2 , -S (O) m CH 3 , -NH-C (O) -CH 3 , -CO 2 CH 3 , OCH 3 , CO 2 H, NO 2 , -NH-C (= NCN) -SCH 3 , -NH-C (= NCN) -NH 2 , -NH-C (O) -NH 2 , -NH-C (O)- C (O) —OR 6 , or —NH—C (O) —C (O) —NR 6 R 7 . 제1항에 있어서, 4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논인 화합물.A compound according to claim 1, which is 4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone. 제1항에 있어서, 1-(4-아미노벤질-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논인 화합물.A compound according to claim 1, which is 1- (4-aminobenzyl-4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone. 제1항에 있어서, 화합물이 1-(4-아미노벤질-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, 1-(4-아미노벤질-4-(3-사이클로펜틸옥시-4-메톡시페닐)-3-메틸-2-이미다졸리디논, 4-(3-사이클로펜틸옥시-4-메톡시페닐)-1-(4-디메틸아미노벤질)-2-이미다졸리디논, 4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, 1-4(아세트아미노벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(-)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(+)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-1-(4-아미노벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(+)-1-(4-아미노벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-1-(4-벤질피리딜-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(+)-1-(4-벤질피리딜-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-1-(4-아세트아미노벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(+)-1-(4-아세트아미노벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-1-(4-옥사미도벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(+)-1-(4-옥사미도벤질-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(+)-1-(4-포름아미도벤질-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-1-(4-포름아미도벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, 1-(4-아세트아미도-3-피리딜메틸)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-1-(2,4-디아미노벤질)-2-이미다졸리디논, S-(-)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-1-(2,4-디아세트아미도벤질)-2-이미다졸리디논, R-(+)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-1-(2,4-디아미노벤질)-2-이미다졸리디논, 또는 R-(+)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-1-(2,4-디아세트아미도벤질)-2-이미다졸리디논중에서 선택되는 화합물.The compound of claim 1, wherein the compound is 1- (4-aminobenzyl-4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, 1- (4-aminobenzyl-4- ( 3-cyclopentyloxy-4-methoxyphenyl) -3-methyl-2-imidazolidinone, 4- (3-cyclopentyloxy-4-methoxyphenyl) -1- (4-dimethylaminobenzyl)- 2-imidazolidinone, 4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, 1-4 (acetaminobenzyl) -4- (3-cyclopentyloxy-4- Methoxyphenyl) -2-imidazolidinone, R-(-)-4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S-(+)-4- ( 3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S-(-)-1- (4-aminobenzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) 2-imidazolidinone, R-(+)-1- (4-aminobenzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S-(- ) -1- (4-benzylpyridyl-4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, R-(+)-1- (4-benzyl Ridyl-4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S-(-)-1- (4-acetaminobenzyl) -4- (3-cyclopentyloxy- 4-methoxyphenyl) -2-imidazolidinone, R-(+)-1- (4-acetaminobenzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imida Zolidinone, S-(-)-1- (4-oxamidobenzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, R-(+)-1- (4-oxamidobenzyl-4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, R-(+)-1- (4-formamidobenzyl-4- (3 -Cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S-(-)-1- (4-formamidobenzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl ) -2-imidazolidinone, 1- (4-acetamido-3-pyridylmethyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S- (-)-4- (3-cyclopentyloxy-4-methoxyphenyl) -1- (2,4-diaminobenzyl) -2-imidazolidinone, S-(-)-4- (3- Cyclopentyloxy-4-methoxy Phenyl) -1- (2,4-diacetamidobenzyl) -2-imidazolidinone, R-(+)-4- (3-cyclopentyloxy-4-methoxyphenyl) -1- (2 , 4-diaminobenzyl) -2-imidazolidinone, or R-(+)-4- (3-cyclopentyloxy-4-methoxyphenyl) -1- (2,4-diacetamidobenzyl ) -2-imidazolidinone. 종양괴사인자의 생성억제 유효량의 제1항에 따른 화합물을 이를 필요로하는 동물에 투여하여 동물체내에서 종양괴사인자의 종양괴사인자의 생성을 억제하는 방법.Inhibition of production of tumor necrosis factor A method of inhibiting the production of tumor necrosis factor of tumor necrosis factor in an animal by administering an effective amount of a compound according to claim 1 to an animal in need thereof. 제16항에 있어서, X가 YR2이고, 할로겐이 모두 불소인 방법.The method of claim 16, wherein X is YR 2 and all of the halogens are fluorine. 제17항에 있어서, Y가 산소이고, R5가 H, 임의로 치환된 -(CH2)qAr또는 임의로 치환된 C1-6알킬인 방법.The method of claim 17, wherein Y is oxygen and R 5 is H, optionally substituted — (CH 2 ) q Ar or optionally substituted C 1-6 alkyl. 제18항에 있어서, R1이 사이클로펜틸, CH3,,,, 또는 할로치환된 알킬이고, R2가 메틸 또는 할로치환된 알킬인 방법. 19. The compound of claim 18, wherein R 1 is cyclopentyl, CH 3 , , , Or halosubstituted alkyl and R 2 is methyl or halosubstituted alkyl. 제19항에 있어서, q가 1이고 Ar이 -NH2, -N(CH3)2, -S(O)mCH3, -NH-C(O)-CH3, NHC(O)NH2, CO2CH3, OCH3, NO2, -NHC(=NCN)NH2, -NHC-(-NCN)SCH3, -NHC(O)-C(O)-OCH3, -NHC(O)-C(O)-NH2또는 COOCH3에 의해 임의로 치환된 페닐인 방법.The compound of claim 19, wherein q is 1 and Ar is —NH 2 , —N (CH 3 ) 2 , —S (O) m CH 3 , —NH—C (O) —CH 3 , NHC (O) NH 2 , CO 2 CH 3 , OCH 3 , NO 2 , -NHC (= NCN) NH 2 , -NHC-(-NCN) SCH 3 , -NHC (O) -C (O) -OCH 3 , -NHC (O) -C (O) -NH 2 or phenyl optionally substituted by COOCH 3 . 제16항에 있어서, 화합물이 1-(4-아미노벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, 1-(4-아미노벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-3-메틸-2-이미다졸리디논, 4-(3-사이클로펜틸옥시-4-메톡시페닐)-1-(4-디메틸아미노벤질)-2-이미다졸리디논, 4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, 1-(4-아세트아미노벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(-)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(+)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-1-(4-아미노벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(+)-1-(4-아미노벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-1-(4-벤질피리딜)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(+)-1-(4-벤질피리딜)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-1-(4-아세트아미도벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(+)-1-(4-아세트아미도벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-1-(4-옥사미도벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(+)-1-(4-옥사미도벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, R-(+)-1-(4-포름아미도벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-1-(4-포름아미도벤질)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, 1-(4-아세트아미도-3-피리딜메틸)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-2-이미다졸리디논, S-(-)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-1-(2,4-디아미노벤질)-2-이미다졸리디논, S-(-)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-1-(2,4-디아세트아미도벤질)-2-이미다졸리디논, R-(+)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-1-(2,4-디아미노벤질)-2-이미다졸리디논, 또는R-(+)-4-(3-사이클로펜틸옥시-4-메톡시페닐)-1-(2,4-디아세트아미도벤질)-2-이미다졸리디논중에서 선택되는 방법.The compound of claim 16, wherein the compound is 1- (4-aminobenzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, 1- (4-aminobenzyl) -4 -(3-cyclopentyloxy-4-methoxyphenyl) -3-methyl-2-imidazolidinone, 4- (3-cyclopentyloxy-4-methoxyphenyl) -1- (4-dimethylaminobenzyl ) -2-imidazolidinone, 4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, 1- (4-acetaminobenzyl) -4- (3-cyclopentyloxy 4-methoxyphenyl) -2-imidazolidinone, R-(-)-4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S-(+)- 4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S-(-)-1- (4-aminobenzyl) -4- (3-cyclopentyloxy-4-meth Methoxyphenyl) -2-imidazolidinone, R-(+)-1- (4-aminobenzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S -(-)-1- (4-benzylpyridyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, R-(+)-1- (4- Zylpyridyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S-(-)-1- (4-acetamidobenzyl) -4- (3- Cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, R-(+)-1- (4-acetamidobenzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) 2-imidazolidinone, S-(-)-1- (4-oxamidobenzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, R- ( +)-1- (4-oxamidobenzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, R-(+)-1- (4-formamido Benzyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2-imidazolidinone, S-(-)-1- (4-formamidobenzyl) -4- (3-cyclopentyl Oxy-4-methoxyphenyl) -2-imidazolidinone, 1- (4-acetamido-3-pyridylmethyl) -4- (3-cyclopentyloxy-4-methoxyphenyl) -2- Imidazolidinone, S-(-)-4- (3-cyclopentyloxy-4-methoxyphenyl) -1- (2,4-diaminobenzyl) -2-imidazolidinone, S-(- ) -4- (3-cyclopentyloxy-4- Methoxyphenyl) -1- (2,4-diacetamidobenzyl) -2-imidazolidinone, R-(+)-4- (3-cyclopentyloxy-4-methoxyphenyl) -1- ( 2,4-diaminobenzyl) -2-imidazolidinone, or R-(+)-4- (3-cyclopentyloxy-4-methoxyphenyl) -1- (2,4-diacetamido Benzyl) -2-imidazolidinone. 제16항에 있어서, TNF의 억제가 폐혈병성쇼크, 내독성쇼크, 그람음성폐혈증, 또는 독성쇼크증후군의 질병상태를 중재하는 방법.The method of claim 16, wherein the inhibition of TNF mediates the disease state of pulmonary pulmonary shock, toxic shock, Gram-negative pulmonary syndrome, or toxic shock syndrome. 제16항에 있어서, TNF의 억제가 후천성 면역결핍증후군의 속발성악액질, 암의 속발성악액질, 급성면역결핍증후군(AIDS), 또는 AIDS 연관된 복합증(ARC)의 질병상태, 또는 HIV감염과 연관된 모든 다른 질병상태, 또는 인플루앤자 및 CMV로 이루어진 그룹중에서 선택된 바이러스의 감염증을 중재하는 방법.17. The method of claim 16, wherein the inhibition of TNF is secondary to cachexia of the acquired immunodeficiency syndrome, secondary cachexia of cancer, acute immunodeficiency syndrome (AIDS), or a disease state of AIDS-associated complications (ARC), or any other disease associated with HIV infection. A method of mediating a disease state or infection of a virus selected from the group consisting of influenza and CMV. 제16항에 있어서, TNF의 억제가 성인호흡장애증후군, 천식, 만성폐렴질환, 크론병, 궤양성대장염, 골흡수 또는 이식체와 숙주의 반응의 질병상태를 중재하는 방법.17. The method of claim 16, wherein the inhibition of TNF mediates the respiratory distress syndrome, asthma, chronic pneumonia disease, Crohn's disease, ulcerative colitis, bone resorption or disease state of the reaction of the implant and host. 유효량의 제1항에 따른 화합물과 약제학적으로 허용되는 담체 또는 희석제를 함유한 약제학적 조성물.A pharmaceutical composition comprising an effective amount of a compound according to claim 1 and a pharmaceutically acceptable carrier or diluent. 일반식(Ⅰa)의 화합물 또는 이의 약제학적으로 허용되는 염:Compound of Formula (Ia) or a pharmaceutically acceptable salt thereof: 상기 식에서, R1은 -CH2-C3사이클릭알킬, -CH2-C5-6사이클로알킬, C4-6사이클로알킬테트라하이드로푸란, 사이클로펜테닐, 한개이사의 불소에 의해 임의로 치환된 -C1-7알킬, -(CH2)2-4OH, -(CH2)n-C(O)O(CH2)m-CH3또는 -(CH2)p-O-(CH2)mCH3이고, 여기서, 이들 모두는 한개 내지 세개의 메틸그룹 또는 한개의 에틸그룹에 의해 임의로 치환될 수 있으며, m은 0내지 2의 수이고, n은 1내지 3의 수이고, p는 2또는 3의 수이고, X는 YR2이고, 여기서, Y는 O또는 S이고, R2는 한개이상의 불소에 의해 임의로 치환된 -CH2또는 CH2CH3이고, R3는 H, CH3, CN, CH2F, CHF2또는 CF3이고, R4는 H,C1-4알킬, OH, OCH3, OCH2CH3또는 OAc이고, R5는 H, OH, -(CH2)qAr 또는 C1-6알킬이고, 여기서 Ar및 C1-6알킬은 F, Br, Cl, NO2,NR6R7, CO2R6, -NH-C(=NCN)-SCH3,-NHC(O)-NR6R7, -C(O)NR6R7, -NHC(O)CH3, -NH-(=NCN)-NR6R7, -NHC(O)C(O)-NR6R7, -NHSO2CH3, -S(O)mCH3, -NHC(O)C(O)-OR6,-OR6, -CN, -C(=NR6)-NR6R7, -NHSO2CF3,또는중의 한개이상에 의해 치환되거나 비치환될수 있으며, Ar은 2-, 3- 또는 4-피리딜, 피리미딜, 피라질, 이미다졸릴, 모노폴리노 또는 페닐이고, R6및 R7은 독립적으로 수소 또는 C1-4알킬이고, q는 0내지 2의 수이다.Wherein R 1 is optionally substituted by -CH 2 -C 3 cyclicalkyl, -CH 2 -C 5-6 cycloalkyl, C 4-6 cycloalkyltetrahydrofuran, cyclopentenyl, one fluorine -C 1-7 alkyl, - (CH 2) 2-4 OH , - (CH 2) n -C (O) O (CH 2) m -CH 3 or - (CH 2) pO- (CH 2) m CH 3 , wherein all of these may be optionally substituted by one to three methyl groups or one ethyl group, m is 0 to 2, n is 1 to 3, p is 2 or Is a number of 3, X is YR 2 , wherein Y is O or S, R 2 is —CH 2 or CH 2 CH 3 optionally substituted with one or more fluorine, and R 3 is H, CH 3 , CN , CH 2 F, CHF 2 or CF 3 , R 4 is H, C 1-4 alkyl, OH, OCH 3 , OCH 2 CH 3 or OAc, R 5 is H, OH,-(CH 2 ) q Ar Or C 1-6 alkyl, wherein Ar and C 1-6 alkyl are F, Br, Cl, NO 2, NR 6 R 7 , CO 2 R 6 , -NH-C (= NCN) -SCH 3, -NHC (O) -NR 6 R 7 , -C (O) NR 6 R 7 , -NH C (O) CH 3 , -NH-(= NCN) -NR 6 R 7 , -NHC (O) C (O) -NR 6 R 7 , -NHSO 2 CH 3 , -S (O) m CH 3 , -NHC (O) C (O) -OR 6 , -OR 6 , -CN, -C (= NR 6 ) -NR 6 R 7 , -NHSO 2 CF 3 , or Which may be unsubstituted or substituted by one or more of: Ar is 2-, 3- or 4-pyridyl, pyrimidyl, pyrazyl, imidazolyl, monopolyo or phenyl, and R 6 and R 7 are independently hydrogen Or C 1-4 alkyl, q is a number from 0 to 2. 제26항에 있어서, R1이 한개 내지 세개의 메틸그룹 또는 한개의 에틸그룹에 의해 임의로 치환된-CH3, -CHF2, C1-7알킬, -C1-4알킬 OH, 또는 C4-C5사이 클릭알킬인 화합물.The compound of claim 26, wherein R 1 is optionally substituted by one to three methyl groups or one ethyl group. -CH 3 , -CHF 2 , C 1-7 alkyl, -C 1-4 alkyl OH, or C 4 -C 5 cyclicalkyl. 유효량의 제26항에 따른 화합물과 약제학적으로 허용되는 담체 또는 희석제를 함유한 약제학적 조성물.A pharmaceutical composition comprising an effective amount of a compound according to claim 26 and a pharmaceutically acceptable carrier or diluent. PDE IV를 억제시키기에 충분한 유효량의 제27항에 따른 화합물을 이를 필요로하는 포유동물에 투여하여, PDE IV를 억제하는 방법.A method of inhibiting PDE IV by administering to a mammal in need thereof an effective amount of a compound according to claim 27 sufficient to inhibit PDE IV. 제29항에 있어서, PDE IV의 억제가 천식의 질병상태, 또는 알레르기 또는 염증질병을 중재하는 방법.The method of claim 29, wherein the inhibition of PDE IV mediates a disease state of asthma, or allergy or inflammatory disease. PDE IV를 억제시키기에 유효한 량의 제13항 또는 제14항에 따른 화합물을 이를 필요로하는 포유동물에 투여하여, 천식을 치료하는 방법.A method of treating asthma by administering to a mammal in need thereof an effective amount of the compound according to claim 13 or 14 to inhibit PDE IV. PDE IV를 억제시키기에 유효한 량의 제13항, 제14항 또는 제15항에 따른 화합물을 이를 필요로하는 포유동물에 투여하여, PDE IV를 억제하는 방법.A method for inhibiting PDE IV by administering to a mammal in need thereof an effective amount of the compound according to claim 13, 14 or 15 to inhibit PDE IV. (A)R5가 H인 일반식(5)의 화합물을 알데하이드옥심으로 산화시킨다음, 이 옥심을 환원시켜 R5가 하이드록실인 일반식(5)의 상응하는 화합물을 수득한 후, 염기 및 용매로 폐환시켜, R5가 H이고 R3이 CN이 아닌 다른 것인 일반식(Ⅰ)의 화합물을 수득하거나, (B) R5가 H인 일반식(5)의 화합물을 알데하이드와 반응시킨다음 산염을 형성하고, 생성된 이미늄염을 환원시켜 R3이 CN이 아닌 다른것이고, R5가 H가 아닌 다른것인 일반식(5)의 화합물을 생성한 다음, 이것을 염기로 페환시켜 R3이 CN이 아닌 다른것이고, R5가 H가 아닌 다른것이고 X가 Br, I, NO2, 아민, S(O)m, 또는 포르밀아민이 아닌 다른것이고 m이 1또는 2인 일반식(Ⅰ)의 화합물을 수득하거나, (C)R4와 R5가 H이고, R3이 CONH2인 일반식(5)의 화합물을 폐환시킨 후 R3아미드를 니트릴로 탈수시켜 R5및 R4가 H이고 R3이 CN인 일반식(Ⅰ)의 화합물을 수득하거나, (D) R4및 R5가 H이고 R3이 CONH2인 일반식(5)의 적절히 보호된 아미노잔기를 반응시키고, R3아미드를 니트릴로 탈수시킨다음, 아민 작용기를 탈보호시켜 R4및 R5가 H이고 R3이 CN인 일반식(5)의 화합물을 수득한 후, 이것을 폐환시켜 R4가 수소이고 R5가 H가 아닌 다른것이고 R3이 CN인 일반식(Ⅰ)의 화합물을 수득하거나, (E) 단계(D)에서 생성된 일반식(5)의 탈보호된 아민작용기를 동족체화한 후 폐환시켜 R4가 수소이고 R5가 H가 아닌 다른것이고 R3이 CN인 일반식(Ⅰ)의 화합물을 수득하거나, (F) 일반식(6)의 화합물을 산스캐빈저의 존재하에 용매중에서 포스겐과 반응시켜 R5가 H이고 R3이 CN이 아닌 다른것이 일반식(Ⅰ)의 화합물을 수득하거나, (G) 일반식(6)의 화합물을 용매중에서 N.N′-카보닐디이미다졸 또는 1,1-카보닐디-1,2,4-트리아졸과 반응시켜 R5가 H이고 R3이 CN이 아닌 다른것인 일반식(Ⅰ)의 화합물을 수득하거나, (H)R4가 H이고 R3이 CONH2인 일반식(6)의 화합물을 폐환반응시킨 후 아미드 탈수시켜 R4및 R5가 H이고 R3이 CN인 일반식(Ⅰ)의 화합물을 수득하거나, (Ⅰ) α-NH가 보호되고, R5가 H이고 R3이 CN이 아닌 일반식(6)의 화합물을 반응시키고 적절한 알데하이드로 이민을 형성시킨 후, 이민 또는 임미늄 이온환원 및 α-NH의 탈보호를 수행하여 R5가 H가 아닌 다른것이고 R3이 CN이 아닌 다른것인 일반식(6)의 화합물을 수득한 다음, 이어서 상기 단계(F)내지 (H)중 어느것이라도 수행하여 일반식(Ⅰ)의 화합물을 수득하여, 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염을 제조하는 방법:(A) The compound of formula (5) wherein R 5 is H is oxidized to aldehyde oxime, and then the oxime is reduced to give the corresponding compound of formula (5) wherein R 5 is hydroxyl, and then the base and Ring closure to obtain a compound of formula (I) wherein R 5 is H and R 3 is other than CN, or (B) a compound of formula (5) wherein R 5 is H is reacted with an aldehyde Next, an acid salt is formed and the resulting iminium salt is reduced to give a compound of formula (5) wherein R 3 is anything other than CN, and R 5 is something other than H, and then ringed with a base to give R 3. Is other than CN, R 5 is not H and X is Br, I, NO 2 , amine, S (O) m , or other than formylamine, and m is 1 or 2 ), Or (C) ring-closing the compound of formula (5) wherein R 4 and R 5 are H and R 3 is CONH 2 , followed by dehydration of the R 3 amide with nitrile R 5 And a compound of formula (I) wherein R 4 is H and R 3 is CN, or (D) a suitably protected amino residue of formula (5) wherein R 4 and R 5 are H and R 3 is CONH 2 And R 3 amide is dehydrated with nitrile, followed by deprotection of the amine functional group to give a compound of formula (5) wherein R 4 and R 5 are H and R 3 is CN, which is then ring-closed to R 4 Is hydrogen, R 5 is other than H and R 3 is CN, to obtain a compound of formula (I), or (E) a deprotected amine functional group of formula (5) produced in step (D) And cyclization to obtain a compound of formula (I) wherein R 4 is hydrogen, R 5 is other than H and R 3 is CN, or (F) the compound of formula (6) is present in the presence of a is reacted with phosgene in a solvent R 5 is H and R 3 is different to obtain a compound represented by the general formula (ⅰ) non-CN, or, NN the compound of (G), formula (6) in a solvent - carbonyldiimidazole imidazole or 1,1-carbonyldiimidazole is reacted with 1,2,4-triazole R 5 is H and R 3 a to give a compound of formula (Ⅰ) other non-CN, or ( H) ring closure of the compound of formula (6) wherein R 4 is H and R 3 is CONH 2 , followed by amide dehydration to obtain a compound of formula (I) wherein R 4 and R 5 are H and R 3 is CN Or (I) reacting a compound of formula (6) wherein α-NH is protected, R 5 is H and R 3 is not CN, and forms an appropriate aldehyde imine, followed by imine or imimium ion reduction and α Deprotection of —NH to give a compound of formula (6) wherein R 5 is anything other than H and R 3 is other than CN, and then any of steps (F) to (H) above To obtain a compound of formula (I) to prepare a compound of formula (I) or a pharmaceutically acceptable salt thereof: 상기식에서, R1은 -(CR9R10)n-(C(O)O)r-(CR9R10)m-R8, -(CR9R10)n-(C(O)NR6)r-(CR9R10)m-R8, 또는 -(CR9R10)n-(O)s-(CR9R10)m-R8이고, 여기서, 알킬잔기는 하나이상의 할로겐에 의해 임의로 치환될 수 있고, n은 0내지 4의 수이고, m은 0내지 2의 수이고, r은 0또는 1의 수이고, s는 0또는 1의 수이고, R9및 R10은 수소 또는 C1-2알킬중에서 독립적으로 선택되고, R8은 수소, 메틸, 하이드록실, 테트라하이드로푸란, 테트라하이드로피란, 테트라하이드로티오펜, 테트라하이드로티오피란, C3-6사이클로알킬, 또는 한개 또는 두개의 불포화결합을 함유한 C4-6사이클로알킬이고, 여기서, 사이클로알킬 및 헤테로사이클잔기는 1내지 3개의 메틸그룹 또는 한개의 에틸그룹에 의해 임의로 치환될 수 있고, 단, a) r이 1일때, n은 1내지 4이거나, b) s가 1일때, n은 2내지 4이거나, c) R8이 하이드록실이고, r이 1이고, n이 1내지 4일때, m은 2이거나, d) R8이 하이드록실이고, r또는 s가 0일때, n+m의 합이 2내지 6이거나, e) -(CR9R10)n-(C(O)O)r-(CR9R10)m-R8에서 m이 0이고, r이 1일때, n은 1내지 4이거나, f) R8이 2-테트라하이드로피란 또는 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, r또는 s가 0일때, n+m의 합이 1내지 6이거나, g)R8이 2-테트라하이드로피란, 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, n이 1내지 4이고, r이 1일때, m은 1내지 2이어야하거나, h) R8이 2-테트라하이드로피란, 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, n은 2내지 4이고, s는 1일때, m은 1내지 2이어야하고, X는 YR2, 할로겐, 니트로, NR6R7또는 포르밀아민이고, 여기서, Y는 0또는 S(O)m′이고, m′은 0내지 2의 수이고, R6및 R7은 하기정의한 바와같고, R2는 1개이상의 할로겐에 의해 임의로 치환된 -CH3또는 -CH2CH3이고, R3은 H, CH3, CN, CH2F, CHF2, 또는 CF3이고, R4는 H, C1-C4알킬, OH, OCH3, OCH2CH3, 또는 OAc이고, R5는 H, OH, (CH2)qAr, 또는 C1-6알킬이고, 여기서, -(CH2)qAr, 또는 C1-6알킬그룹은 F, Br, Cl, -NO2, -NR6R7, -CO2R6, -OR6, -OC(O)R6, C(O)R6, CN, -C(O)-NR6R7, -C(S)-NR6R7, -NR6-C(O)-NR6R7, -NR6-C(S)-NR6R7, -NR6-C(O)-R6, -NR6-C(S)-R6, -NR6-C(O)-OR6, C(=NR6)-NR6R7, -C(=NCN)-NR6R7, -C(=NCN)-SR6, -NR6-C(=NCN)-SR6, -NR6-C(=NCN)-NR6R7, -C(=NR6R7)SR6, -NR6-S(O)2-R6, -S(O)m'-R6, -NR6SO2-CF3, -NR6-C(O)-C(O)-NR6R7, -NR6-C(O)-C(O)-OR6, 1-이미다졸릴 또는 1-(NR6)-2-이미다졸릴에 의해 한번이상 임으로 치환되고, Ar은 2-,3- 또는 4-피리딜, 피리미딜, 피라질, 이미다졸릴, 모르폴리노, 4- 또는 5-티아졸릴, 트리아졸릴, 2-또는 3-티에닐, 2-티아펜 또는 페닐이고, R6및 R7은 독립적으로 수소이거나, 한개 이상의 할로겐에 의해 임의로 치환된 C1-4알킬이고, q는 0내지 2의 수이다.Wherein R 1 is-(CR 9 R 10 ) n- (C (O) O) r- (CR 9 R 10 ) m -R 8 ,-(CR 9 R 10 ) n- (C (O) NR 6 ) r- (CR 9 R 10 ) m -R 8 , or-(CR 9 R 10 ) n- (O) s- (CR 9 R 10 ) m -R 8 , wherein the alkyl residue is one or more halogen May be optionally substituted by n is 0 to 4, m is 0 to 2, r is 0 or 1, s is 0 or 1, and R 9 and R 10 are Independently selected from hydrogen or C 1-2 alkyl, R 8 is hydrogen, methyl, hydroxyl, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, C 3-6 cycloalkyl, or one Or C 4-6 cycloalkyl containing two unsaturated bonds, wherein the cycloalkyl and heterocycle residues may be optionally substituted by one to three methyl groups or one ethyl group, provided that a) r is When 1, n is 1 to 4, or b) when s is 1, n is 2 Not 4 or, c) R and 8 is hydroxyl, and r is 1, or n is 1 to 4 when, m is 2, d) R and 8 is hydroxyl, r, or s of a is 0, n + m When the sum is 2 to 6 or e)-(CR 9 R 10 ) n- (C (O) O) r- (CR 9 R 10 ) m -R 8 , when m is 0 and r is 1, n is 1 to 4 or f) when R 8 is 2-tetrahydropyran or 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene and r or s is 0, the sum of n + m is 1 to 6, or g) when R 8 is 2-tetrahydropyran, 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene, n is 1-4 and r is 1, m Is 1 to 2, or h) when R 8 is 2-tetrahydropyran, 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene, n is 2 to 4 and s is 1 , m is 1 or 2, and must be, X is YR 2, halogen, you A, NR 6 R 7 or formyl amine, wherein, "a, m, Y is O or S (O) m is a number of 0 to 2, R 6 and R 7 are as defined for, R 2 is -CH 3 or -CH 2 CH 3 , optionally substituted by one or more halogens, R 3 is H, CH 3 , CN, CH 2 F, CHF 2 , or CF 3 , and R 4 is H, C 1- C 4 alkyl, OH, OCH 3 , OCH 2 CH 3 , or OAc, R 5 is H, OH, (CH 2 ) q Ar, or C 1-6 alkyl, wherein — (CH 2 ) q Ar, Or C 1-6 alkyl group is F, Br, Cl, -NO 2 , -NR 6 R 7 , -CO 2 R 6 , -OR 6 , -OC (O) R 6 , C (O) R 6 , CN , -C (O) -NR 6 R 7 , -C (S) -NR 6 R 7 , -NR 6 -C (O) -NR 6 R 7 , -NR 6 -C (S) -NR 6 R 7 , -NR 6 -C (O) -R 6 , -NR 6 -C (S) -R 6 , -NR 6 -C (O) -OR 6 , C (= NR 6 ) -NR 6 R 7 ,- C (= NCN) -NR 6 R 7 , -C (= NCN) -SR 6 , -NR 6 -C (= NCN) -SR 6 , -NR 6 -C (= NCN) -NR 6 R 7 ,- C (= NR 6 R 7 ) SR 6 , -NR 6 -S (O) 2 -R 6 , -S (O) m ' -R 6 , -NR 6 SO 2 -CF 3 , -NR 6 -C ( In O) -C (O) -NR 6 R 7 , -NR 6 -C (O) -C (O) -OR 6 , 1-imidazolyl or 1- (NR 6 ) -2-imidazolyl Is substituted one or more times, and Ar is 2-, 3- or 4-pyridyl, pyrimidyl, pyrazyl, imidazolyl, morpholino, 4- or 5-thiazolyl, triazolyl, 2-or 3- Thienyl, 2-thiaphene or phenyl, R 6 and R 7 are independently hydrogen or C 1-4 alkyl optionally substituted by one or more halogens, q is a number from 0 to 2. 일반식(5)의 화합물:Compound of formula (5): 상기식에서, R1은 -(CR9R10)n-(C(O)O)r-(CR9R10)m-R8, -(CR9R10)n-(C(O)NR6)r-(CR9R10)m-R8, 또는 -(CR9R10)n-(O)s-(CR9R10)m-R8이고, 여기서, 알킬잔기는 하나이상의 할로겐에 의해 임의로 치환될 수 있고, n은 0내지 4의 수이고, m은 0내지 2의 수이고, r은 0또는 1의 수이고, s는 0또는 1의 수이고, R9및 R10은 수소 또는 C1-2알킬중에서 독립적으로 선택되고, R8은 수소, 메틸, 하이드록실, 테트라하이드로푸란, 테트라하이드로피란, 테트라하이드로티오펜, 테트라하이드로티오피란, C3-6사이클로알킬, 또는 한개 또는 두개의 불포화결합을 함유한 C4-6사이클로알킬이고, 여기서, 사이클로알킬 및 헤테로사이클잔기는 1내지 3개의 메틸그룹 또는 한개의 에틸그룹에 의해 임의로 치환될 수 있고, 단, a) r이 1일때, n은 1내지 4이거나, b) s가 1일때, n은 2내지 4이거나, c) R8이 하이드록실이고, r이 1이고, n이 1내지 4일때, m은 2이거나, d) R8이 하이드록실이고, r또는 s가 0일때, n+m의 합이 2내지 6이거나, e) -(CR9R10)n-(C(O)O)r-(CR9R10)m-R8에서 m이 0이고, r이 1일때, n은 1내지 4이거나, f) R8이 2-테트라하이드로피란 또는 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, r또는 s가 0일때, n+m의 합이 1내지 6이거나, g)R8이 2-테트라하이드로피란, 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, n이 1내지 4이고, r이 1일때, m은 1내지 2이어야하거나, h) R8이 2-테트라하이드로피란, 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, n은 2내지 4이고, s는 1일때, m은 1내지 2이어야하고, X는 YR2, 할로겐, 니트로, NR6R7또는 포르밀아민이고, 여기서, Y는 0또는 S(O)m′이고, m′은 0내지 2의 수이고, R6및 R7은 하기정의한 바와같고, R2는 1개이상의 할로겐에 의해 임의로 치환된 -CH3또는 -CH2CH3이고, R3은 H, CH3, CN, CH2F, CHF2, 또는 CF3이고, R4는 H, C1-C4알킬, OH, OCH3, OCH2CH3, 또는 OAc이고, R5는 H, OH, -(CH2)qAr, 또는 C1-6알킬이고, 여기서, (CH2)qAr, 또는 C1-6알킬그룹은 F, Br, Cl, -NO2, -NR6R7, -CO2R6, -OR6, -OC(O)R6, C(O)R6, CN, -C(O)-NR6R7, -C(S)-NR6R7, -NR6-C(O)-NR6R7, -NR6-C(S)-NR6R7, -NR6-C(O)-R6, -NR6-C(S)-R6, -NR6-C(O)-OR6, C(=NR6)-NR6R7, -C(=NCN)-NR6R7, -C(=NCN)-SR6, -NR6-C(=NCN)-SR6, -NR6-C(=NCN)-NR6R7, -C(=NR6R7)SR6, -NR6-S(O)2-R6, -S(O)m'-R6, -NR6SO2-CF3, -NR6-C(O)-C(O)-NR6R7, -NR6-C(O)-C(O)-OR6, 1-이미다졸릴 또는 1-(NR6)-2-이미다졸릴에 의해 한번이상 임으로 치환되고, Ar은 2-, 3- 또는 4-피리딜, 피리미딜, 피라질, 이미다졸릴, 모르폴리노, 4- 또는 5-티아졸릴, 트리아졸릴, 2-또는 3-티에닐, 2-티아펜 또는 페닐이고, R6및 R7은 독립적으로 수소이거나, 한개 이상의 할로겐에 의해 임의로 치환된 C1-4알킬이고, q는 0내지 2의 수이다.Wherein R 1 is-(CR 9 R 10 ) n- (C (O) O) r- (CR 9 R 10 ) m -R 8 ,-(CR 9 R 10 ) n- (C (O) NR 6 ) r- (CR 9 R 10 ) m -R 8 , or-(CR 9 R 10 ) n- (O) s- (CR 9 R 10 ) m -R 8 , wherein the alkyl residue is one or more halogen May be optionally substituted by n is 0 to 4, m is 0 to 2, r is 0 or 1, s is 0 or 1, and R 9 and R 10 are Independently selected from hydrogen or C 1-2 alkyl, R 8 is hydrogen, methyl, hydroxyl, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, C 3-6 cycloalkyl, or one Or C 4-6 cycloalkyl containing two unsaturated bonds, wherein the cycloalkyl and heterocycle residues may be optionally substituted by one to three methyl groups or one ethyl group, provided that a) r is When 1, n is 1 to 4, or b) when s is 1, n is 2 Not 4 or, c) R and 8 is hydroxyl, and r is 1, or n is 1 to 4 when, m is 2, d) R and 8 is hydroxyl, r, or s of a is 0, n + m When the sum is 2 to 6 or e)-(CR 9 R 10 ) n- (C (O) O) r- (CR 9 R 10 ) m -R 8 , when m is 0 and r is 1, n is 1 to 4 or f) when R 8 is 2-tetrahydropyran or 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene and r or s is 0, the sum of n + m is 1 to 6, or g) when R 8 is 2-tetrahydropyran, 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene, n is 1-4 and r is 1, m Is 1 to 2, or h) when R 8 is 2-tetrahydropyran, 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene, n is 2 to 4 and s is 1 , m is 1 or 2, and must be, X is YR 2, halogen, you A, NR 6 R 7 or formyl amine, wherein, "a, m, Y is O or S (O) m is a number of 0 to 2, R 6 and R 7 are as defined for, R 2 is -CH 3 or -CH 2 CH 3 , optionally substituted by one or more halogens, R 3 is H, CH 3 , CN, CH 2 F, CHF 2 , or CF 3 , and R 4 is H, C 1- C 4 alkyl, OH, OCH 3 , OCH 2 CH 3 , or OAc, R 5 is H, OH, — (CH 2 ) q Ar, or C 1-6 alkyl, wherein (CH 2 ) q Ar, Or C 1-6 alkyl group is F, Br, Cl, -NO 2 , -NR 6 R 7 , -CO 2 R 6 , -OR 6 , -OC (O) R 6 , C (O) R 6 , CN , -C (O) -NR 6 R 7 , -C (S) -NR 6 R 7 , -NR 6 -C (O) -NR 6 R 7 , -NR 6 -C (S) -NR 6 R 7 , -NR 6 -C (O) -R 6 , -NR 6 -C (S) -R 6 , -NR 6 -C (O) -OR 6 , C (= NR 6 ) -NR 6 R 7 ,- C (= NCN) -NR 6 R 7 , -C (= NCN) -SR 6 , -NR 6 -C (= NCN) -SR 6 , -NR 6 -C (= NCN) -NR 6 R 7 ,- C (= NR 6 R 7 ) SR 6 , -NR 6 -S (O) 2 -R 6 , -S (O) m ' -R 6 , -NR 6 SO 2 -CF 3 , -NR 6 -C ( In O) -C (O) -NR 6 R 7 , -NR 6 -C (O) -C (O) -OR 6 , 1-imidazolyl or 1- (NR 6 ) -2-imidazolyl Is substituted one or more times, and Ar is 2-, 3- or 4-pyridyl, pyrimidyl, pyrazyl, imidazolyl, morpholino, 4- or 5-thiazolyl, triazolyl, 2- or 3- Thienyl, 2-thiaphene or phenyl, R 6 and R 7 are independently hydrogen or C 1-4 alkyl optionally substituted by one or more halogens, q is a number from 0 to 2. 제34항에 있어서, (2R)-1-벤질옥시카보닐아미노-2-(3-사이클로펜틸옥시-4-메톡시페닐)-2-〔(-)-멘틸옥시카보닐아미노〕에탄 또는2(S)-1-벤질옥시카보닐아미노-2-(3-사이클로펜틸옥시-4-메톡시페닐)-2-〔(-)-멘틸옥시카보닐아미노〕에탄인 화합물.The method of claim 34, wherein (2R) -1-benzyloxycarbonylamino-2- (3-cyclopentyloxy-4-methoxyphenyl) -2-[(-)-mentyloxycarbonylamino] ethane or 2 (S) -1-Benzyloxycarbonylamino-2- (3-cyclopentyloxy-4-methoxyphenyl) -2-[(-)-menthyloxycarbonylamino] ethane. 일반식(6)의 화합물:Compound of formula (6): 상기식에서, R1은 -(CR9R10)n-(C(O)O)r-(CR9R10)m-R8, -(CR9R10)n-(C(O)NR6)r-(CR9R10)m-R8, 또는 -(CR9R10)n-(C)s-(CR9R10)m-R8이고, 여기서, 알킬잔기는 하나이상의 할로겐에 의해 임의로 치환될 수 있고, n은 0내지 4의 수이고, m은 0내지 2의 수이고, r은 0또는 1의 수이고, s는 0또는 1의 수이고, R9및 R10은 수소 또는 C1-2알킬중에서 독립적으로 선택되고, R8은 수소, 메틸, 하이드록실, 테트라하이드로푸란, 테트라하이드로피란, 테트라하이드로티오펜, 테트라하이드로티오피란, C3-6사이클로알킬, 또는 한개 또는 두개의 불포화결합을 함유한 C4-6사이클로알킬이고, 여기서, 사이클로알킬 및 헤테로사이클잔기는 1내지 3개의 메틸그룹 또는 한개의 에틸그룹에 의해 임의로 치환될 수 있고, 단, a) r이 1일때, n은 1내지 4이거나, b) s가 1일때, n은 2내지 4이거나, c) R8이 하이드록실이고, r이 1이고, n이 1내지 4일때, m은 2이거나, d) R8이 하이드록실이고, r또는 s가 0일때, n+m의 합이 2내지 6이거나, e) -(CR9R10)n-(C(O)O)r-(CR9R10)m-R8에서 m이 0이고, r이 1일때, n은 1내지 4이거나, f) R8이 2-테트라하이드로피란 또는 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, r또는 s가 0일때, n+m의 합이 1내지 6이거나, g)R8이 2-테트라하이드로피란, 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, n이 1내지 4이고, r이 1일때, m은 1내지 2이어야하거나, h) R8이 2-테트라하이드로피란, 2-테트라하이드로티오피란, 2-테트라하이드로푸란 또는 2-테트라하이드로티오펜이고, n은 2내지 4이고, s는 1일때, m은 1내지 2이어야하고, X는 YR2, 할로겐, 니트로, NR6R7또는 포르밀아민이고, 여기서, Y는 0또는 S(O)m′이고, m′은 0내지 2의 수이고, R6및 R7은 하기정의한 바와같고, R2는 1개이상의 할로겐에 의해 임의로 치환된 -CH3또는 -CH2CH3이고, R3은 H, CH3, CN, CH2F, CHF2, 또는 CF3이고, R4는 H, C1-C4알킬, OH, OCH3, OCH2CH3, 또는 OAc이고, R5는 H, OH, -(CH2)qAr, 또는 C1-6알킬이고, 여기서, (CH2)qAr, 또는 C1-6알킬그룹은 F, Br, Cl, -NO2, -NR6R7, -CO2R6, -OR6, -OC(O)R6, C(O)R6, CN, -C(O)-NR6R7, -C(S)-NR6R7, -NR6-C(O)-NR6R7, -NR6-C(S)-NR6R7, -NR6-C(O)-R6, -NR6-C(S)-R6, -NR6-C(O)-OR6, C(=NR6)-NR6R7, -C(=NCN)-NR6R7, -C(=NCN)-SR6, -NR6-C(=NCN)-SR6, -NR6-C(=NCN)-NR6R7, -C(=NR6R7)SR6, -NR6-S(O)2-R6, -S(O)m-R6, -NR6SO2-CF3, -NR6-C(O)-C(O)-NR6R7, -NR6-C(O)-C(O)-OR6, 1-이미다졸릴 또는 1-(NR6)-2-이미다졸릴에 의해 한번이상 임으로 치환되고, Ar은 2-, 3- 또는 4-피리딜, 피리미딜, 피라질, 이미다졸릴, 모르폴리노, 4- 또는 5-티아졸릴, 트리아졸릴, 2-또는 3-티에닐, 2-티아펜 또는 페닐이고, R6및 R7은 독립적으로 수소이거나, 한개 이상의 할로겐에 의해 임의로 치환된 C1-4알킬이고, q는 0내지 2의 수이다.Wherein R 1 is-(CR 9 R 10 ) n- (C (O) O) r- (CR 9 R 10 ) m -R 8 ,-(CR 9 R 10 ) n- (C (O) NR 6 ) r- (CR 9 R 10 ) m -R 8 , or-(CR 9 R 10 ) n- (C) s- (CR 9 R 10 ) m -R 8 , wherein the alkyl residue is one or more halogen May be optionally substituted by n is 0 to 4, m is 0 to 2, r is 0 or 1, s is 0 or 1, and R 9 and R 10 are Independently selected from hydrogen or C 1-2 alkyl, R 8 is hydrogen, methyl, hydroxyl, tetrahydrofuran, tetrahydropyran, tetrahydrothiophene, tetrahydrothiopyran, C 3-6 cycloalkyl, or one Or C 4-6 cycloalkyl containing two unsaturated bonds, wherein the cycloalkyl and heterocycle residues may be optionally substituted by one to three methyl groups or one ethyl group, provided that a) r is When 1, n is 1 to 4, or b) when s is 1, n is 2 Not 4 or, c) R and 8 is hydroxyl, and r is 1, or n is 1 to 4 when, m is 2, d) R and 8 is hydroxyl, r, or s of a is 0, n + m When the sum is 2 to 6 or e)-(CR 9 R 10 ) n- (C (O) O) r- (CR 9 R 10 ) m -R 8 , when m is 0 and r is 1, n is 1 to 4 or f) when R 8 is 2-tetrahydropyran or 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene and r or s is 0, the sum of n + m is 1 to 6, or g) when R 8 is 2-tetrahydropyran, 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene, n is 1-4 and r is 1, m Is 1 to 2, or h) when R 8 is 2-tetrahydropyran, 2-tetrahydrothiopyran, 2-tetrahydrofuran or 2-tetrahydrothiophene, n is 2 to 4 and s is 1 , m is 1 or 2, and must be, X is YR 2, halogen, you A, NR 6 R 7 or formyl amine, wherein, "a, m, Y is O or S (O) m is a number of 0 to 2, R 6 and R 7 are as defined for, R 2 is -CH 3 or -CH 2 CH 3 , optionally substituted by one or more halogens, R 3 is H, CH 3 , CN, CH 2 F, CHF 2 , or CF 3 , and R 4 is H, C 1- C 4 alkyl, OH, OCH 3 , OCH 2 CH 3 , or OAc, R 5 is H, OH, — (CH 2 ) q Ar, or C 1-6 alkyl, wherein (CH 2 ) q Ar, Or C 1-6 alkyl group is F, Br, Cl, -NO 2 , -NR 6 R 7 , -CO 2 R 6 , -OR 6 , -OC (O) R 6 , C (O) R 6 , CN , -C (O) -NR 6 R 7 , -C (S) -NR 6 R 7 , -NR 6 -C (O) -NR 6 R 7 , -NR 6 -C (S) -NR 6 R 7 , -NR 6 -C (O) -R 6 , -NR 6 -C (S) -R 6 , -NR 6 -C (O) -OR 6 , C (= NR 6 ) -NR 6 R 7 ,- C (= NCN) -NR 6 R 7 , -C (= NCN) -SR 6 , -NR 6 -C (= NCN) -SR 6 , -NR 6 -C (= NCN) -NR 6 R 7 ,- C (= NR 6 R 7 ) SR 6 , -NR 6 -S (O) 2 -R 6 , -S (O) m -R 6 , -NR 6 SO 2 -CF 3 , -NR 6 -C (O ) -C (O) -NR 6 R 7 , -NR 6 -C (O) -C (O) -OR 6 , 1-imidazolyl or 1- (NR 6 ) -2-imidazolyl Is substituted one or more times, and Ar is 2-, 3- or 4-pyridyl, pyrimidyl, pyrazyl, imidazolyl, morpholino, 4- or 5-thiazolyl, triazolyl, 2- or 3- Thienyl, 2-thiaphene or phenyl, R 6 and R 7 are independently hydrogen or C 1-4 alkyl optionally substituted by one or more halogens, q is a number from 0 to 2. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930701375A 1990-11-06 1991-11-05 Imidazolidinone Compound KR930703262A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US60999090A 1990-11-06 1990-11-06
US60998190A 1990-11-06 1990-11-06
US07/609,981 1990-11-06
US07/609,990 1990-11-06
PCT/US1991/008229 WO1992007567A1 (en) 1990-11-06 1991-11-05 Imidazolidinone compounds

Publications (1)

Publication Number Publication Date
KR930703262A true KR930703262A (en) 1993-11-29

Family

ID=27086166

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930701375A KR930703262A (en) 1990-11-06 1991-11-05 Imidazolidinone Compound

Country Status (8)

Country Link
EP (1) EP0557408A4 (en)
JP (1) JPH06501708A (en)
KR (1) KR930703262A (en)
AU (1) AU9030691A (en)
CA (1) CA2095429A1 (en)
IE (1) IE913855A1 (en)
PT (1) PT99442A (en)
WO (1) WO1992007567A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9311281D0 (en) * 1993-06-01 1993-07-21 Rhone Poulenc Rorer Ltd Novel composition of matter
US5698711A (en) 1991-01-28 1997-12-16 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic- or heteroatom-containing linking group
DE69322254T2 (en) * 1992-01-13 1999-04-29 Smithkline Beecham Corp PYRIDYL SUBSTITUTED IMIDAZOLES
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
DK0607373T3 (en) * 1992-06-15 1997-10-13 Celltech Therapeutics Ltd Trisubstituted phenyl derivatives as selective phosphodiesterase IV inhibitors.
IL106517A0 (en) * 1992-07-28 1994-08-26 Rhone Poulenc Rorer Ltd Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic or heteroatom containing linking group
US5679696A (en) * 1992-07-28 1997-10-21 Rhone-Poulenc Rorer Limited Compounds containing phenyl linked to aryl or heteroaryl by an aliphatic-or heteroatom-containing linking group
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
US5814651A (en) * 1992-12-02 1998-09-29 Pfizer Inc. Catechol diethers as selective PDEIV inhibitors
GB9226830D0 (en) * 1992-12-23 1993-02-17 Celltech Ltd Chemical compounds
US5622977A (en) * 1992-12-23 1997-04-22 Celltech Therapeutics Limited Tri-substituted (aryl or heteroaryl) derivatives and pharmaceutical compositions containing the same
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
US5482944A (en) * 1993-07-13 1996-01-09 Pfizer Inc. Pyrimidones and imidazolinones for treatment of shock
EP0714397A1 (en) * 1993-08-19 1996-06-05 Smithkline Beecham Corporation Phenethylamine compounds
US5665754A (en) * 1993-09-20 1997-09-09 Glaxo Wellcome Inc. Substituted pyrrolidines
US5502072A (en) * 1993-11-26 1996-03-26 Pfizer Inc. Substituted oxindoles
ES2139754T3 (en) * 1993-11-26 2000-02-16 Pfizer 3-PHENYL-2-ISOXAZOLINES AS ANTI-INFLAMMATORY AGENTS.
ATE260911T1 (en) * 1993-12-22 2004-03-15 Celltech R&D Ltd TRISUBSUTITUTED PHENYL DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS PHOSPHODIESTERASE (TYPE IV) INHIBITORS
GB9326699D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
GB9326173D0 (en) * 1993-12-22 1994-02-23 Celltech Ltd Chemical compounds and process
AU684887B2 (en) * 1994-03-09 1998-01-08 Pfizer Inc. Isoxazoline compounds as inhibitors of TNF release
CA2184914C (en) * 1994-03-09 2000-09-19 Victoria L. Cohan Isoxazoline compounds as 5-lipoxygenase inhibitors
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
GB9412573D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
US5563143A (en) * 1994-09-21 1996-10-08 Pfizer Inc. Catechol diether compounds as inhibitors of TNF release
TW424087B (en) * 1995-04-06 2001-03-01 Janssen Pharmaceutica Nv 1,3-dihydro-1-(phenylalkenyl)-2H-imidazol-2-one derivatives
TW332201B (en) * 1995-04-06 1998-05-21 Janssen Pharmaceutica Nv 1,3-Dihydro-1-(phenylalkyl)-2H-imidazol-2-one derivatives
DE19540027A1 (en) * 1995-10-27 1997-04-30 Gruenenthal Gmbh Substituted imidazolidine-2,4-dione compounds as active pharmaceutical ingredients
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
DE19617864A1 (en) * 1996-04-23 1997-10-30 Schering Ag New chiral phenyldihydrofuranones
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) * 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
JP2001507349A (en) 1996-12-23 2001-06-05 セルテック セラピューティックス リミテッド Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
DE19732928C2 (en) * 1997-07-31 2000-05-18 Gruenenthal Gmbh Use of substituted imidazolidine-2,4-dione compounds as pain relievers
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
EP2258689A1 (en) * 2000-03-16 2010-12-08 Biolipox AB Benzylated PDE4 inhibitors
ES2293993T3 (en) 2000-05-31 2008-04-01 Santen Pharmaceutical Co., Ltd. TNF-ALFA PRODUCTION INHIBITORS.
MXPA03010810A (en) 2001-05-29 2004-03-22 Schering Ag Cdk inhibiting pyrimidines, production thereof and their use as medicaments.
AU2006335110B2 (en) * 2005-12-30 2011-04-14 Merck Sharp & Dohme Corp. CETP inhibitors
WO2008021309A1 (en) 2006-08-15 2008-02-21 Wyeth Imidazolidin-2-one derivatives useful as pr modulators
TW200815428A (en) 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
US7538107B2 (en) 2006-08-15 2009-05-26 Wyeth Oxazinan-2-one derivatives useful as PR modulators
WO2008021338A2 (en) 2006-08-15 2008-02-21 Wyeth Tricyclic oxazolidone derivatives useful as pr modulators
US7649007B2 (en) 2006-08-15 2010-01-19 Wyeth Llc Oxazolidine derivatives as PR modulators
CN104781256B (en) * 2012-10-29 2017-09-29 霍夫曼-拉罗奇有限公司 3,4 pairs of substitution oxazolidinone derivatives and its purposes as the inhibitor of calcium-activated potassium channel

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4034087A (en) * 1973-12-17 1977-07-05 The Regents Of The University Of Michigan Pharmaceutical composition and process of treatment
HU179019B (en) * 1978-11-01 1982-08-28 Gyogyszekutato Intezet Process for preparing 4-//3,4-dialkoxy-phenyl/-alkyl/- 2imidazolidinone derivatives
HU215433B (en) * 1986-04-29 2000-05-28 Pfizer Inc. Process for producing new 2-oxo-5-phenyl-pyrimidin derivatives
DE3823299A1 (en) * 1988-07-07 1990-01-11 Schering Ag SUBSTITUTED PHENYL-PYRROLIDIN-2-ONE, -OXAZOLIDIN-2-ONE AND -IMIDAZOLIDIN-2-ONE, THEIR PRODUCTION AND USE IN MEDICINAL PRODUCTS

Also Published As

Publication number Publication date
EP0557408A4 (en) 1993-10-27
AU9030691A (en) 1992-05-26
WO1992007567A1 (en) 1992-05-14
IE913855A1 (en) 1992-05-22
JPH06501708A (en) 1994-02-24
PT99442A (en) 1992-09-30
CA2095429A1 (en) 1992-05-07
EP0557408A1 (en) 1993-09-01

Similar Documents

Publication Publication Date Title
KR930703262A (en) Imidazolidinone Compound
US7169791B2 (en) Inhibitors of tyrosine kinases
US7135471B2 (en) Aryl oximes
JP4135318B2 (en) Novel pyrimidine-5-carboxamide derivatives
JP2983636B2 (en) Pharmacologically active pyridine derivative and method for producing the same
CA2396590A1 (en) 2-amino-nicotinamide derivatives and their use as vegf-receptor tyrosine kinase inhibitors
JP3787307B2 (en) N-substituted carbamoyloxyalkylazolium derivatives
JP2016509591A (en) Novel antiviral agent against HBV infection
EP1098644A1 (en) Substituted benzimidazole antiviral agents
KR100723072B1 (en) - nf-b inhibitors and uses thereof
KR100647386B1 (en) NF-kB INHIBITORS AND USES THEREOF
US7098215B2 (en) Nitrogenous compounds and antiviral drugs containing the same
RU2005141496A (en) NITROGEN-CONTAINING HETEROARYL DERIVATIVES
CA2742903A1 (en) Novel bis-amides as antimalarial agents
JPH0649034A (en) Propenoylimidazole derivative
JP3116256B2 (en) (Thio) urea derivatives
JP2003515586A (en) Acryloyl peptide derivatives, their preparation, and their use as antitumor agents
WO2023196556A1 (en) Cannabinoid receptor 1 antagonists/inverse agonists and uses thereof
JP2023538582A (en) Pyrrolopyridine derivatives and their uses
AU2008202194B2 (en) Inhibitors of tyrosine kinases
WO2023164050A1 (en) Compounds as glp-1r agonists

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid